The CagriSema phase 2 paper and what a fixed combination buys — the long version Writing it up because I had to work it out twice and would rather nobody else did.
A narrow question about CagriSema phase 2 paper, deliberately narrow, because the broad version has been asked here four times and produced four long threads and no answer.
One question, stated units, stated method, and what I have already ruled out.
Where I part company with the opening post, and it is a narrow parting.
Reading the phase 2 paper: it establishes tolerability and efficacy in a selected population on a defined dose escalation. It does not establish the lowest effective dose or the durability over years.
The opening post is the version of this I will quote in future. One addition.
Amylin signalling is distinct from GLP-1 signalling. Amylin slows gastric emptying and promotes satiety through a different receptor and different neural pathways. The hypothesis behind combination is two complementary satiety mechanisms with one injection.
A qualification I should have led with rather than closed on.
On CagriSema phase 2 paper, the part that usually goes wrong is that the question is asked as though it has one answer. It has a range, and the width of the range is the interesting bit.
If you can post the two or three numbers you are working from, several people here will check the arithmetic rather than argue about the conclusion.
Is synergy the right word for the combination data? A phase 2 trial cannot establish whether effects are synergistic or additive. Synergy is a mechanistic claim that requires a designed experiment to support it. The combination works, but the mechanism is unsettled.
I had written a reply contradicting post #5 and deleted it. Here is what survived.
Worth distinguishing the combination product from the two components bought separately and mixed. Those are different pharmaceutical objects and nothing published about the first applies to the second.
Happy to be the one who is wrong here if it settles the question.
Everything in post #5 holds. The case it does not cover is the one I have.
Cagrilintide alone is discussed less than in combination because the published data is almost entirely from combination trials. The phase 2 combination data was consistent with more effect than either component alone, but phase 2 cannot establish whether that is synergy or simply additivity.
Narrowing post #9, because the general version has more than one answer.
Combination products complicate the certificate question considerably. Two active components mean two purity determinations and a ratio, and a single figure for a combination tells you almost nothing.
What I would check first on CagriSema phase 2 paper is whether the thing being measured moved or whether the way of measuring it moved. Those look identical in a graph.
I had read the opposite somewhere and cannot now find where, which tells me something.
Adding the measurement that post #10 says would settle it.
The interest in combining it with semaglutide is that two different satiety mechanisms might add. Whether they do, and by how much, is exactly what the combination trials were designed to find out rather than something to be assumed.
This is the version I would want a new member to read first.
Post #13 describes the usual case. This is about the unusual one.
The phase 3 combination programme is where the clinically interesting numbers will come from. Phase 2 established that the combination does something; the size of it in a larger population is a separate question.
That is where I would start, not where I would stop.
Post #14 is the version of this I will quote in future. One addition.
Published human data on cagrilintide alone is thinner than on the combination, which is the reverse of what most people assume from how it is discussed here.
That matches what I was told, which is not the same as knowing it.
I would be cautious about generalising from the CagriSema phase 2 paper example above. It is a good example. It is one example.
Answering the question post #16 raises rather than the one it answers.
The monoisotopic mass sits near 3749.9 Da, and the same caveat applies as everywhere else: a mass consistent with the proposed structure is a necessary condition and not a sufficient one.
A weak preference rather than a position.
The CagriSema phase 2 paper: a fixed combination of the two components in one weekly injection. The trade-off of a fixed combination is that you cannot titrate the components independently and you cannot attribute effect to one component from a combination trial.
Written in the hope of being told what I have missed.
Post #16 put the caveat in the right place and I want to underline it.
Nausea appears in the amylin-analogue literature as it does in the incretin literature, and the two are not additive in a simple way when the drugs are combined. The combination trials report tolerability separately for that reason.
I am reporting what happened, not recommending it.
Everything in post #17 holds. The case it does not cover is the one I have.
Gastric emptying: both amylin and GLP-1 slow it, through partly overlapping but distinct mechanisms. Whether the slowing at a higher magnitude produces disproportionate nausea or is tolerable is a question phase 3 exists to answer.
If it helps: the failure mode here is usually boring rather than dramatic.
Narrowing post #21, because the general version has more than one answer.
The honest summary of the evidence base: a coherent mechanism, good phase 2 data in combination, and much less standalone human data than the volume of discussion implies.
I have changed my mind on this once already, so take it as current rather than settled.
On CagriSema phase 2 paper the community has more anecdote than the confidence in this thread implies, and I include my own contribution in that.
Two questions I would want answered before drawing anything from the CagriSema phase 2 paper data above: how were the cases selected, and what happened to the ones that dropped out.
Answering the question post #21 raises rather than the one it answers.
Research-use-only cagrilintide is not approved for human use and the published evidence base is a clinical-trial evidence base. Those two facts sit uncomfortably together and both are true.
Amylin analogues affect gastric emptying as well, so the mechanism overlaps the incretins in at least one place. That overlap is part of why the combination's tolerability profile is not simply the sum of the two.
Posting my CagriSema phase 2 paper numbers with the method attached so they can be discounted properly. Uncontrolled, unblinded, and collected by someone who wanted a particular answer.
The thing about CagriSema phase 2 paper that took me longest to accept is that a plausible mechanism is not evidence of an effect. It is a reason to look, not a result.
On storage: aggregation-prone peptides are the ones where repeated warming and cooling does the most damage, and where a solution that looks fine may already have changed. Visual inspection is a weaker test here than usual.
The interesting part of this is the exception, and I do not understand the exception.